Olubunmi Bolaji, MD
Hospice and Palliative Medicine · Commack, NYNPI 1619100633
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 31.3% of the total. 2025 is the largest year on record at $444, 6.4 times the $70 reported in 2021. Among hospice and palliative medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $25.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$400
- Exact Sciences$138
- Teva Pharmaceuticals USA, Inc.$104
- Somnomed Inc.$100
- AstraZeneca$89
- Lundbeck LLC$70
- plus $379 from 15 others
What the payments were for
- Food & beverage$1,279100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $400 |
| Exact Sciences | 2 | $138 |
| Teva Pharmaceuticals USA, Inc. | 5 | $104 |
| Somnomed Inc. | 1 | $100 |
| AstraZeneca | 5 | $89 |
| Lundbeck LLC | 4 | $70 |
| GSK | 3 | $54 |
| Novo Nordisk | 2 | $42 |
| Cumberland Pharmaceuticals, Inc. | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Abbott | 1 | $26 |
| Renalytix AI, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Pfizer | 1 | $22 |
| Dexcom, Inc. | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Phadia US Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Medicomp Inc | 1 | $13 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,279 in reported general payments places this provider in the 90th percentile of 133 hospice and palliative medicine providers in New York.
See all hospice and palliative medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 141 | $105,011 |
| EliquisApixaban | 126 | $63,181 |
| OzempicSemaglutide | 43 | $45,285 |
| AustedoDeutetrabenazine | 12 | $43,702 |
| FarxigaDapagliflozin Propanediol | 41 | $40,847 |
| JardianceEmpagliflozin | 26 | $22,926 |
| MounjaroTirzepatide | 16 | $19,673 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $17,336 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $17,201 |
| LinzessLinaclotide | 14 | $16,268 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 46 | $13,037 |
| GemtesaVibegron | 52 | $12,835 |
| BrilintaTicagrelor | 38 | $11,879 |
| VraylarCariprazine Hcl | 14 | $9,726 |
| TrintellixVortioxetine Hydrobromide | 18 | $8,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $22 | $63,181126 claims |
| AstraZenecaFarxiga, Brilinta | $89 | $52,72579 claims |
| Novo NordiskOzempic | $42 | $45,28543 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $104 | $43,70212 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $54 | $21,02032 claims |
| Lilly USA, LLCMounjaro | $23 | $19,67316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 133 hospice and palliative medicine providers in New York.
Other hospice and palliative medicine in Commack
- Gregory PiskunBrooklyn$902K
- Jane SimpsonJohnson City$11K
- Stella RubinaAstoria$3K
- Jinny CaldenteyNew Hyde Park$3K
- Jeffrey BergerMineola$3K
- Sherly AbrahamBrooklyn$2K
- Ines CarrasquilloSyracuse$2K
- Julissa BaezNew York$2K
- Milagros SilvaNew York$2K
- Alexander LoreckBrooklyn$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.